
Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
2
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
3
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
4
New Biomarkers, Drug Targets Identified for Colorectal Cancer
5